Trials / Recruiting
RecruitingNCT07077434
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
A Phase 1 Open-Label, Multi-Center Study to Evaluate Pharmacokinetics, Safety and Tolerability of BMS-986504 in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986504 in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986504 | Specified dose on specified days |
Timeline
- Start date
- 2025-10-15
- Primary completion
- 2027-01-19
- Completion
- 2027-01-19
- First posted
- 2025-07-22
- Last updated
- 2026-01-05
Locations
12 sites across 2 countries: China, Japan
Source: ClinicalTrials.gov record NCT07077434. Inclusion in this directory is not an endorsement.